Albrecht Stenzinger, M.D.


Jonathan Nowak, M.D.,Ph.D.

Description: Approaches to calculating, reporting, and interpreting Tumor Mutational Burden (TMB) testing will be discussed in this second of two updates on the broader use of TMB as a potentially prognostic and predictive tool in clinical care. Dr. Stenzinger will provide an overview of how large-scale efforts to harmonize TMB measurement may bolster the potential clinical utility of TMB reporting.

Duration: 1 hr

Level of Instruction: Basic

This webinar is part 2 of a two-part series exploring the role of TMB testing in relationship to other tumor biomarkers as well as the standardization of TMB testing.

This program has been supported through an educational grant from Bristol-Myers Squibb.

Course Objectives
  • Discuss the current state of TMB calculation and reporting as well as efforts to standardize this process across laboratories.
  • Understand the potential clinical utility of TMB and how it should be interpreted, especially in the context of other immunotherapy biomarkers.
  • Harness available information to improve implementation of molecularly targeted cancer diagnostics and therapies in the clinical setting.
Course Information
Date Presented:
August 15, 2019 11:00 AM Eastern
1 hour
AMP Regular Member Price:
AMP Technologist Member Price:
AMP Associate Member Price:
Non-member Price:
Registration for this event is closed
LIVE WEBINAR: TMB Relevance in the Clinic: Evaluating Test Results and Asking the Right Questions to Determine the Best Care
Individual topic purchase: Selected